化学原料药名称：BETAMETHASONE 倍他米松 药品生产商/持有人：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 证书编号：CEP 2024-446-Rev 00 发证机关：欧洲药品质量管理局（EDQM） 有效期：自 2026 年 2 月 11 日起五年内有效 二、原料药的相关情况 倍他米松是一种主要用于治疗过敏和自身免疫性炎症的激素类药物，能够帮 助身体减轻炎症反应，防止组织因过度炎症受损，同时抑制免疫系统过度反应和 过敏现象。 公司于 2024 年 9 月向 EDQM 提交了倍他米松（原料药）的 CEP 申请。EDQM 官网显示，除斯瑞药业外，全球倍他米松原料药生产企业中有 7 家持有有效的 CEP 证书。根据 IQVIA 数据统计，倍他米松原料药 2024 年全球需求量近 2 吨。 证券代码：300583 证券简称：赛托生物 公告编号：2026-007 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公 ...

证券代码：300583 证券简称：赛托生物 公告编号：2026-006 山东赛托生物科技股份有限公司 关于公司及子公司重大诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：法院已立案受理，尚未正式开庭审理。 2、上市公司所处的当事人地位：山东赛托生物科技股份有限公司（以下简 称"公司"）及控股子公司山东斯瑞药业有限公司（以下简称"斯瑞药业"）为 被告一、被告二。 3、涉案的金额：原告起诉状诉讼请求的金额为 22,600 万元人民币，此金额 包含原告根据斯瑞药业公开环评报告信息计算利得 22,560 万元和其他费用 40 万元。该涉案金额仅为原告起诉状所载诉讼请求的金额，不代表法院最终审理结 果。 4、对上市公司损益产生的影响：公司产品均为自主研发，公司对原告主张 不予认可，并将积极应诉。公司为甾体药物龙头企业，并实现了"甾体药物核心 原料-中间体-高端中间体-原料药-制剂"一体化产业布局，产品品类较多，本次 专利诉讼仅涉及一款中间体产品，其占公司主营业务收入比例较低。本次诉讼尚 未开庭审理，后续判决结果存在不确 ...

Group 1 - The core focus of the company is on business development and qualification certification, particularly in high-end respiratory active pharmaceutical ingredients [1] - The company has a strategy to adjust pricing based on market conditions to expand channels and increase market share [1] - The subsidiary, Sry Pharmaceutical, has received a high-tech enterprise certificate valid for three years, indicating the company's strengthening in innovation and technology capabilities [1] Group 2 - The stock price of the company has shown fluctuations over the past week, ranging from 14.81 yuan to 14.99 yuan, with a total change of 1.35% and a volatility of 3.72% [2] - Trading volume and turnover rate have remained active, with a single-day increase of 1.69% on February 9, followed by a decrease of 0.66% on February 11 [2] - The current stock price is close to the 20-day moving average, indicating some short-term pressure in the technical analysis [2] Group 3 - Institutional interest in the company is moderate, with a neutral sentiment prevailing in public opinion [3] - Two institutions have provided profit forecasts, expecting a net profit growth of 29.12% in 2025 and 17.67% in 2026, suggesting continued revenue expansion [3] - Institutional ratings are neutral with no clear target price, and the low proportion of institutional holdings reflects market caution regarding the company's short-term outlook [3]

Group 1 - The core point of the article is that Saito Bio has announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, which will benefit the company with a reduced corporate income tax rate of 15% for three consecutive years starting from 2025 [2] Group 2 - The high-tech enterprise certificate is issued by multiple authorities including the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Industry and Information Technology, the Shandong Provincial Department of Finance, and the State Taxation Administration of Shandong Province [2] - The certification is valid for three years, indicating the company's ongoing commitment to innovation and technology development [2] - This tax incentive is expected to enhance the company's financial performance and support its growth strategy in the pharmaceutical industry [2]

Core Viewpoint - SaiTuo Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has passed the high-tech enterprise review and obtained the high-tech enterprise certificate issued by various governmental bodies in Shandong Province, valid for three years [1] Group 1 - The high-tech enterprise certificate was issued by the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Industry and Information Technology, the Shandong Provincial Department of Finance, and the State Taxation Administration of Shandong Province [1] - The certificate was issued on December 8, 2025, with the certificate number GR202537002998 [1]

Group 1 - The core point of the article is that Saito Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has passed the high-tech enterprise review and obtained the high-tech enterprise certificate [1] - The certificate was issued by multiple authorities including the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Industry and Information Technology, the Shandong Provincial Department of Finance, and the State Taxation Administration of Shandong Province [1] - The certificate was issued on December 8, 2025, and is valid for three years [1]

证券代码：300583 证券简称：赛托生物 公告编号：2026-005 山东赛托生物科技股份有限公司 关于控股子公司再次获得高新技术企业证书的公告 山东赛托生物科技股份有限公司 二〇二六年二月六日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司（以下简称"斯瑞药业"）已通过高新技术企业审查并于近日取得 由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山 东省税务局联合颁发的高新技术企业证书原件，发证时间：2025 年 12 月 8 日， 证书编号为：GR202537002998，有效期三年。 根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相关税收 规定，斯瑞药业自通过高新技术企业认定的当年起三年内享受国家关于高新技术 企业的相关税收优惠政策，按 15%的税率缴纳企业所得税。此次高新技术企业证 书的重新认定，是对其技术实力及研发水平的肯定，对公司的经营发展产生积极 影响。 特此公告。 董事会 ...

Core Viewpoint - Saito Bio has announced a projected net loss for the year 2025, indicating significant financial challenges ahead due to various factors affecting its operations [1] Financial Performance - The company expects a net loss attributable to shareholders of between 63 million and 88 million yuan for the year 2025 [1] - The projected net loss, excluding non-recurring items, is anticipated to be between 66 million and 91 million yuan [1] Reasons for Performance Change - A decline in product market prices has led to a year-on-year decrease in overall gross margin, resulting in reduced gross profit [1] - As a high-tech biotechnology company focused on research and development, Saito Bio has increased its R&D expenditures, contributing to the decrease in net profit for the reporting period [1] - The company has recognized significant inventory impairment provisions for several intermediate products due to falling product prices, which has negatively impacted current profits [1]

Core Viewpoint - The company expects a net profit loss of 63 to 88 million yuan for the fiscal year 2025 due to declining product prices and increased R&D expenses [1] Group 1: Financial Performance - The overall gross profit margin of the company's products has decreased year-on-year due to falling market prices [1] - The company has increased its R&D investment during the reporting period, contributing to the reduction in net profit [1] - Significant inventory impairment provisions were made for several intermediate products due to price declines, impacting current profits [1]

Financial Performance - The company expects a net profit loss between 63 million to 88 million CNY for the year 2025, compared to a loss of 88.77 million CNY in the same period last year[5] - The net profit loss after deducting non-recurring gains and losses is projected to be between 66 million to 91 million CNY, compared to a loss of 103.36 million CNY in the previous year[5] Reasons for Performance Decline - The primary reasons for the performance decline include a decrease in product market prices leading to a lower overall gross margin and reduced profits[7] - The company has increased its R&D investment during the reporting period, contributing to the decrease in net profit[7] - Significant inventory impairment provisions were made for several intermediate products due to price declines, impacting current profits[7] Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with further details to be disclosed in the 2025 annual report[8]